bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figures S1-S11 from Relapse-Fated Latent Diagnosis Subclones in Acute B Lineage Leukemia Are Drug Tolerant and Possess Distinct Metabolic Programs
Authors: Dobson Stephanie M. , García-Prat Laura , Vanner Robert J. , Wintersinger Jeffrey , Waanders Esmé , Gu Zhaohui , McLeod Jessica , Gan Olga I. , Grandal Ildiko , Payne-Turner Debbie , Edmonson Michael N. , Ma Xiaotu , Fan Yiping , Voisin Veronique , Chan-Seng-Yue Michelle , Xie Stephanie Z. , Hosseini Mohsen , Abelson Sagi , Gupta Pankaj , Rusch Michael , Shao Ying , Olsen Scott R. , Neale Geoffrey , Chan Steven M. , Bader Gary , Easton John , Guidos Cynthia J. , Danska Jayne S. , Zhang Jinghui , Minden Mark D. , Morris Quaid , Mullighan Charles G. , Dick John E.
Published: April 2023

Supplementary Figures S1-S11
Supplementary Data S2 from Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages
Authors: Marigo Ilaria , Trovato Rosalinda , Hofer Francesca , Ingangi Vincenzo , De Sanctis Francesco , Ugel Stefano , Canè Stefania , Simonelli Anna , Lamolinara Alessia , Iezzi Manuela , Fassan Matteo , Rugge Massimo , Boschi Federico , Borile Giulia , Eisenhaure Thomas , Sarkizova Siranush , Lieb David , Hacohen Nir , Azzolin Luca , Piccolo Stefano , Lawlor Rita , Scarpa Aldo , Carbognin Luisa , Bria Emilio , Bicciato Silvio , Murray Peter J. , Bronte Vincenzo
Published: April 2023

Marker genes for macrophages clusters from WT and Dab2 KO samples. Related to Fig. 1C-D
CD-20-0142R1_Supplementary_Table_S9.xlsx from BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition
Authors: Hofmann Marco H. , Gmachl Michael , Ramharter Juergen , Savarese Fabio , Gerlach Daniel , Marszalek Joseph R. , Sanderson Michael P. , Kessler Dirk , Trapani Francesca , Arnhof Heribert , Rumpel Klaus , Botesteanu Dana-Adriana , Ettmayer Peter , Gerstberger Thomas , Kofink Christiane , Wunberg Tobias , Zoephel Andreas , Fu Szu-Chin , Teh Jessica L. , Böttcher Jark , Pototschnig Nikolai , Schachinger Franziska , Schipany Katharina , Lieb Simone , Vellano Christopher P. , O'Connell Jonathan C. , Mendes Rachel L. , Moll Jurgen , Petronczki Mark , Heffernan Timothy P. , Pearson Mark , McConnell Darryl B. , Kraut Norbert
Published: April 2023

Table S9
Supplementary Table S6 from Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts
Authors: Elyada Ela , Bolisetty Mohan , Laise Pasquale , Flynn William F. , Courtois Elise T. , Burkhart Richard A. , Teinor Jonathan A. , Belleau Pascal , Biffi Giulia , Lucito Matthew S. , Sivajothi Santhosh , Armstrong Todd D. , Engle Dannielle D. , Yu Kenneth H. , Hao Yuan , Wolfgang Christopher L. , Park Youngkyu , Preall Jonathan , Jaffee Elizabeth M. , Califano Andrea , Robson Paul , Tuveson David A.
Published: April 2023

Supplementary Table S6 shows marker genes of the different human ductal cell sub-clusters
Supplementary Table S15 from Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts
Authors: Elyada Ela , Bolisetty Mohan , Laise Pasquale , Flynn William F. , Courtois Elise T. , Burkhart Richard A. , Teinor Jonathan A. , Belleau Pascal , Biffi Giulia , Lucito Matthew S. , Sivajothi Santhosh , Armstrong Todd D. , Engle Dannielle D. , Yu Kenneth H. , Hao Yuan , Wolfgang Christopher L. , Park Youngkyu , Preall Jonathan , Jaffee Elizabeth M. , Califano Andrea , Robson Paul , Tuveson David A.
Published: April 2023

Supplementary Table S15 shows protein activity of signaling molecules in human CAFs, as analyzed by VIPER
Supplementary Table S14 from Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts
Authors: Elyada Ela , Bolisetty Mohan , Laise Pasquale , Flynn William F. , Courtois Elise T. , Burkhart Richard A. , Teinor Jonathan A. , Belleau Pascal , Biffi Giulia , Lucito Matthew S. , Sivajothi Santhosh , Armstrong Todd D. , Engle Dannielle D. , Yu Kenneth H. , Hao Yuan , Wolfgang Christopher L. , Park Youngkyu , Preall Jonathan , Jaffee Elizabeth M. , Califano Andrea , Robson Paul , Tuveson David A.
Published: April 2023

Supplementary Table S14 shows GSEA of human PDAC myCAFs vs. iCAFs
Supplementary Table from An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth
Authors: Lam Hubert , McNeil Lisa K. , Starobinets Hanna , DeVault Victoria L. , Cohen Roger B. , Twardowski Przemyslaw , Johnson Melissa L. , Gillison Maura L. , Stein Mark N. , Vaishampayan Ulka N. , DeCillis Arthur P. , Foti James J. , Vemulapalli Vijetha , Tjon Emily , Ferber Kyle , DeOliveira Daniel B. , Broom Wendy , Agnihotri Parul , Jaffee Elizabeth M. , Wong Kwok-Kin , Drake Charles G. , Carroll Pamela M. , Davis Thomas A. , Flechtner Jessica Baker
Published: April 2023

Supplementary Table from An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth
Table S6 from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells
Authors: Kumar Sushil , Zeng Zexian , Bagati Archis , Tay Rong En , Sanz Lionel A. , Hartono Stella R. , Ito Yoshinaga , Abderazzaq Fieda , Hatchi Elodie , Jiang Peng , Cartwright Adam N.R. , Olawoyin Olamide , Mathewson Nathan D. , Pyrdol Jason W. , Li Mamie Z. , Doench John G. , Booker Matthew A. , Tolstorukov Michael Y. , Elledge Stephen J. , Chédin Frédéric , Liu X. Shirley , Wucherpfennig Kai W.
Published: April 2023

gRNA and primer sequences
Table S1 from Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression
Authors: Saghafinia Sadegh , Homicsko Krisztian , Di Domenico Annunziata , Wullschleger Stephan , Perren Aurel , Marinoni Ilaria , Ciriello Giovanni , Michael Iacovos P. , Hanahan Douglas
Published: April 2023

Supplementary Table S1
Figure S4 from Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression
Authors: Saghafinia Sadegh , Homicsko Krisztian , Di Domenico Annunziata , Wullschleger Stephan , Perren Aurel , Marinoni Ilaria , Ciriello Giovanni , Michael Iacovos P. , Hanahan Douglas
Published: April 2023

Supplementary Figure S4
Figure S1 from Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression
Authors: Saghafinia Sadegh , Homicsko Krisztian , Di Domenico Annunziata , Wullschleger Stephan , Perren Aurel , Marinoni Ilaria , Ciriello Giovanni , Michael Iacovos P. , Hanahan Douglas
Published: April 2023

Supplementary Figure S1
Supplementary Video S2 from Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
Authors: Chen Hsuan-An , Ho Yu-Jui , Mezzadra Riccardo , Adrover Jose M. , Smolkin Ryan , Zhu Changyu , Woess Katharina , Bernstein Nicholas , Schmitt Georgia , Fong Linda , Luan Wei , Wuest Alexandra , Tian Sha , Li Xiang , Broderick Caroline , Hendrickson Ronald C. , Egeblad Mikala , Chen Zhenghao , Alonso-Curbelo Direna , Lowe Scott W.
Published: April 2023

Supplementary Video S2 from Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
Supplementary Figure S1-S16 from Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
Authors: Chen Hsuan-An , Ho Yu-Jui , Mezzadra Riccardo , Adrover Jose M. , Smolkin Ryan , Zhu Changyu , Woess Katharina , Bernstein Nicholas , Schmitt Georgia , Fong Linda , Luan Wei , Wuest Alexandra , Tian Sha , Li Xiang , Broderick Caroline , Hendrickson Ronald C. , Egeblad Mikala , Chen Zhenghao , Alonso-Curbelo Direna , Lowe Scott W.
Published: April 2023

Supplementary figures complement main figures to show that senescent cells have a rewired environmental signal sensing phenotype, exemplified by an enhanced IFN-g signaling, to facilitate anti-tumor immunity.
Supplementary Notes from Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha
Authors: Sahu Avinash , Wang Xiaoman , Munson Phillip , Klomp Jan P.G. , Wang Xiaoqing , Gu Shengqing Stan , Han Ya , Qian Gege , Nicol Phillip , Zeng Zexian , Wang Chenfei , Tokheim Collin , Zhang Wubing , Fu Jingxin , Wang Jin , Nair Nishanth Ulhas , Rens Joost A.P. , Bourajjaj Meriem , Jansen Bas , Leenders Inge , Lemmers Jaap , Musters Mark , van Zanten Sanne , van Zelst Laura , Worthington Jenny , Liu Jun S. , Juric Dejan , Meyer Clifford A. , Oubrie Arthur , Liu X. Shirley , Fisher David E. , Flaherty Keith T.
Published: April 2023

We detailed a comparison of BipotentR with competing and alternative approaches in Supplementary notes 1, 2, 6, and 7. Supplementary Note 3-5 describes the in vitro findings of ESRRA, the potential clinical relevance of ESRRA across cancer-types, and the association of tumor activity of ESRRA with immune infiltration.
Figure S9 from Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha
Authors: Sahu Avinash , Wang Xiaoman , Munson Phillip , Klomp Jan P.G. , Wang Xiaoqing , Gu Shengqing Stan , Han Ya , Qian Gege , Nicol Phillip , Zeng Zexian , Wang Chenfei , Tokheim Collin , Zhang Wubing , Fu Jingxin , Wang Jin , Nair Nishanth Ulhas , Rens Joost A.P. , Bourajjaj Meriem , Jansen Bas , Leenders Inge , Lemmers Jaap , Musters Mark , van Zanten Sanne , van Zelst Laura , Worthington Jenny , Liu Jun S. , Juric Dejan , Meyer Clifford A. , Oubrie Arthur , Liu X. Shirley , Fisher David E. , Flaherty Keith T.
Published: April 2023

ESRRAi does not affect CD8+T T-cells, and ESRRA activity increases post-immunotherapy in resistant tumors.
Figure S7 from Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha
Authors: Sahu Avinash , Wang Xiaoman , Munson Phillip , Klomp Jan P.G. , Wang Xiaoqing , Gu Shengqing Stan , Han Ya , Qian Gege , Nicol Phillip , Zeng Zexian , Wang Chenfei , Tokheim Collin , Zhang Wubing , Fu Jingxin , Wang Jin , Nair Nishanth Ulhas , Rens Joost A.P. , Bourajjaj Meriem , Jansen Bas , Leenders Inge , Lemmers Jaap , Musters Mark , van Zanten Sanne , van Zelst Laura , Worthington Jenny , Liu Jun S. , Juric Dejan , Meyer Clifford A. , Oubrie Arthur , Liu X. Shirley , Fisher David E. , Flaherty Keith T.
Published: April 2023

Energy metabolism and immune signaling by targeting ESRRA in vitro.
Figure S6 from Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha
Authors: Sahu Avinash , Wang Xiaoman , Munson Phillip , Klomp Jan P.G. , Wang Xiaoqing , Gu Shengqing Stan , Han Ya , Qian Gege , Nicol Phillip , Zeng Zexian , Wang Chenfei , Tokheim Collin , Zhang Wubing , Fu Jingxin , Wang Jin , Nair Nishanth Ulhas , Rens Joost A.P. , Bourajjaj Meriem , Jansen Bas , Leenders Inge , Lemmers Jaap , Musters Mark , van Zanten Sanne , van Zelst Laura , Worthington Jenny , Liu Jun S. , Juric Dejan , Meyer Clifford A. , Oubrie Arthur , Liu X. Shirley , Fisher David E. , Flaherty Keith T.
Published: April 2023

Energy metabolism and immune signaling by targeting ESRRA in vitro.
Figure S17 from Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha
Authors: Sahu Avinash , Wang Xiaoman , Munson Phillip , Klomp Jan P.G. , Wang Xiaoqing , Gu Shengqing Stan , Han Ya , Qian Gege , Nicol Phillip , Zeng Zexian , Wang Chenfei , Tokheim Collin , Zhang Wubing , Fu Jingxin , Wang Jin , Nair Nishanth Ulhas , Rens Joost A.P. , Bourajjaj Meriem , Jansen Bas , Leenders Inge , Lemmers Jaap , Musters Mark , van Zanten Sanne , van Zelst Laura , Worthington Jenny , Liu Jun S. , Juric Dejan , Meyer Clifford A. , Oubrie Arthur , Liu X. Shirley , Fisher David E. , Flaherty Keith T.
Published: April 2023

Overall design.
Figure S11 from Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha
Authors: Sahu Avinash , Wang Xiaoman , Munson Phillip , Klomp Jan P.G. , Wang Xiaoqing , Gu Shengqing Stan , Han Ya , Qian Gege , Nicol Phillip , Zeng Zexian , Wang Chenfei , Tokheim Collin , Zhang Wubing , Fu Jingxin , Wang Jin , Nair Nishanth Ulhas , Rens Joost A.P. , Bourajjaj Meriem , Jansen Bas , Leenders Inge , Lemmers Jaap , Musters Mark , van Zanten Sanne , van Zelst Laura , Worthington Jenny , Liu Jun S. , Juric Dejan , Meyer Clifford A. , Oubrie Arthur , Liu X. Shirley , Fisher David E. , Flaherty Keith T.
Published: April 2023

Machine learning evaluation of immune-metabolic targets in predicting patient response to anti-PD1 and anti-CTLA4 combination therapy.
Supplementary table S1 from Cross-Talk between Myeloid-Derived Suppressor Cells and Mast Cells Mediates Tumor-Specific Immunosuppression in Prostate Cancer
Authors: Jachetti Elena , Cancila Valeria , Rigoni Alice , Bongiovanni Lucia , Cappetti Barbara , Belmonte Beatrice , Enriquez Claudia , Casalini Patrizia , Ostano Paola , Frossi Barbara , Sangaletti Sabina , Chiodoni Claudia , Chiorino Giovanna , Pucillo Carlo E. , Tripodo Claudio , Colombo Mario P.
Published: April 2023

The file contains the list and information of all antibodies used in the study
Supplementary Data from Treg Depletion Licenses T Cell–Driven HEV Neogenesis and Promotes Tumor Destruction
Authors: Colbeck Emily J. , Jones Emma , Hindley James P. , Smart Kathryn , Schulz Ralph , Browne Molly , Cutting Scott , Williams Anwen , Parry Lee , Godkin Andrew , Ware Carl F. , Ager Ann , Gallimore Awen
Published: April 2023

S1. Tumor HEV identified by PNAd staining are also positive for MAdCAM-1. S2. Efficacy of monoclonal antibody treatments to deplete immune cell subsets. S3. Splenic Marginal Zone B cells are profoundly decreased after treatment with LTbetaR.Fc. S4. Splenic Follicular Dendritic Cells and MAdCAM-1 staining are lost after treatment with LTbetaR.Fc or TNFRII.Ig. S5. Lymph Node architecture is disrupted following treatment with LTbetaR.Fc or TNFRII.Ig. S6. Tumor HEV identified by PNAd staining following blockade of LTbetaR or TNFR signalling are also positive for MAdCAM-1. S7. Agonism of LTβR induces formation of High Endothelial Venules in Treg replete tumors, but without concomitant increased T cell infiltration and reduced tumor growth. S8. Relative gene expression of TNF and LTalpha by intratumoral CD4+ and CD8+ T cells and dendritic cells (DC). Data are expressed as fold change in gene expression relative to splenic B cells, and represent two independent experiments.
Supplemental figure S1-S7 from Urinary Bladder Cancer Tregs Suppress MMP2 and Potentially Regulate Invasiveness
Authors: Winerdal Malin E. , Krantz David , Hartana Ciputra A. , Zirakzadeh Ali A. , Linton Ludvig , Bergman Emma A. , Rosenblatt Robert , Vasko Janos , Alamdari Farhood , Hansson Johan , Holmström Benny , Johansson Markus , Winerdal Max , Marits Per , Sherif Amir , Winqvist Ola
Published: April 2023

Supplemental figure 1 illustrates gating strategy appliead to FACS data. Supplemental figure 2 shows gene expression correlation to Treg frequency overlaid on KEGG bladder cancer pathway. Supplemental figure 3 shows expression of functional Treg markers in FOXP3+ and FOXP3- cells from PBMCs and TILs. Supplemental figure 4 compares the phenotype of TIL Tregs from MIBC and non-MIBC tumors. Supplemental figure 5 illustrates post-sort purity sorted populations. Supplemental figure 6 illustrates the correlation of Treg frequency at tumor sublocations to tumor stage and survival. Supplemental figure 7 shows expression level of different MMPs in UBC tumor tissue.
Supplementary Figure Legend from iNKT Cell Cytotoxic Responses Control T-Lymphoma Growth In Vitro and In Vivo
Authors: Bassiri Hamid , Das Rupali , Guan Peng , Barrett David M. , Brennan Patrick J. , Banerjee Pinaki P. , Wiener Susan J. , Orange Jordan S. , Brenner Michael B. , Grupp Stephan A. , Nichols Kim E.
Published: April 2023

PDF file - 80K
Figure S4 from Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy
Authors: Berkeley Robert A. , Steele Lynette P. , Mulder Aat A. , van den Wollenberg Diana J.M. , Kottke Timothy J. , Thompson Jill , Coffey Matthew , Hoeben Rob C. , Vile Richard G. , Melcher Alan , Ilett Elizabeth J.
Published: April 2023

Hand-off of reoNAb by monocytes is contact-dependent
Supplemental Materials, Figures 1 - 4, Tables 1 - 4 from Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
Authors: Beatty Gregory L. , Haas Andrew R. , Maus Marcela V. , Torigian Drew A. , Soulen Michael C. , Plesa Gabriela , Chew Anne , Zhao Yangbing , Levine Bruce L. , Albelda Steven M. , Kalos Michael , June Carl H.
Published: April 2023

Fig. S1. CARTmeso cell manufacturing and treatment schedules. Fig. S2. Detection of human anti-chimeric antibody responses in patients post-CARTmeso cell infusion. Fig. S3. Serum cytokines and chemokines in PDA patient 21211-101. Fig. S4. CARTmeso cytolytic activity against allogeneic and autologous pancreatic cancer cell lines Table S1. Patient demographics. Table S2. Treatment-related adverse events. Table S3. Protoarray analysis of serum samples from mesothelioma patient 17510-105 Table S4. Protoarray analysis of serum samples from pancreatic cancer patient 21211-101
Supplementary Figures 1-4 from CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells
Authors: Pahl Jens H.W. , Koch Joachim , Götz Jana-Julia , Arnold Annette , Reusch Uwe , Gantke Thorsten , Rajkovic Erich , Treder Martin , Cerwenka Adelheid
Published: April 2023

S1. NK cell cytotoxicity and IFNγ are enhanced by AFM13 towards different types of lymphoma cells. S2. Pre-activation by rituximab increases IL2-dependent NK cell proliferation and expansion. S3. Recovery of NK cell function by IL2 or IL15 after AFM13 or rituximab exposure. S4. Pre-activation by AFM13 or rituximab primes enhanced NK cell cytotoxicity.
Supplementary Figure Legends from Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma
Authors: Hogan Sabrina A. , Courtier Anaïs , Cheng Phil F. , Jaberg-Bentele Nicoletta F. , Goldinger Simone M. , Manuel Manuarii , Perez Solène , Plantier Nadia , Mouret Jean-François , Nguyen-Kim Thi Dan Linh , Raaijmakers Marieke I.G. , Kvistborg Pia , Pasqual Nicolas , Haanen John B.A.G. , Dummer Reinhard , Levesque Mitchell P.
Published: April 2023

Figure Legends for Supplemental Figures 1-4
Supplementary Figure Legend from Escalating Regulation of 5T4-Specific IFN-γ+ CD4+ T Cells Distinguishes Colorectal Cancer Patients from Healthy Controls and Provides a Target for In Vivo Therapy
Authors: Scurr Martin , Bloom Anja , Pembroke Tom , Srinivasan Rohit , Brown Clare , Smart Kathryn , Bridgeman Hayley , Davies Mike , Hargest Rachel , Phillips Simon , Christian Adam , Hockey Tom , Gallimore Awen , Godkin Andrew
Published: April 2023

PDF file - 65K
Supplementary Figure 2 from Phenotypic and Functional Activation of Hyporesponsive KIRnegNKG2Aneg Human NK-Cell Precursors Requires IL12p70 Provided by Poly(I:C)-Matured Monocyte-Derived Dendritic Cells
Authors: Curran Shane A. , Romano Emanuela , Kennedy Michael G. , Hsu Katharine C. , Young James W.
Published: April 2023

Induction of NKG2A and KIR expression is dependent on duration of coculture, but not on proliferation. Flow cytometric contour plots illustrating NKG2A (A) and KIR (B) surface expression on initially KIRnegNKG2Aneg NK cells at baseline and following three days (d+3) and six days (d+6) coculture with poly(I:C) matured moDCs. (C-D) KIRnegNKG2Aneg NK cells, stimulated by an equal combination of allogeneic LCcyto and moDCpoly at 10:1 NK:DC ratio were harvested after six days coculture (d+6) and restimulated using freshly matured DCs from the same donors for a further six days (d+12). Stimulated KIRnegNKG2Aneg NK cells were stained for KIR, NKG2A and CD16 expression at both time points. (C) Flow cytometric contour plots illustrating KIR and NKG2A surface expression at d+6 and d+12. (D) Flow cytometric histogram depicting FcgammaRIII (CD16) surface expression at d+6 (dashed line) and d+12 (solid line).
Supplementary Figure Legend from Effect of Montanide and Poly-ICLC Adjuvant on Human Self/Tumor Antigen-Specific CD4+ T Cells in Phase I Overlapping Long Peptide Vaccine Trial
Authors: Tsuji Takemasa , Sabbatini Paul , Jungbluth Achim A. , Ritter Erika , Pan Linda , Ritter Gerd , Ferran Luis , Spriggs David , Salazar Andres M. , Gnjatic Sacha
Published: April 2023

PDF file - 62K
Supplementary Figure 2 from Effect of Montanide and Poly-ICLC Adjuvant on Human Self/Tumor Antigen-Specific CD4+ T Cells in Phase I Overlapping Long Peptide Vaccine Trial
Authors: Tsuji Takemasa , Sabbatini Paul , Jungbluth Achim A. , Ritter Erika , Pan Linda , Ritter Gerd , Ferran Luis , Spriggs David , Salazar Andres M. , Gnjatic Sacha
Published: April 2023

PDF file - 3271K, Comparison of NY-ESO-1-specific cytokine production between 3 cohorts before vaccination. Normalized cytokine production from NY-ESO-1-specific CD4+ T cells before vaccination is shown for statistical consideration. The shape of symbols indicates a single patient as shown in Fig. 1B. Bars indicate mean plus-minus SD. *: p=0.04 by Student's t-test. All other pairs show no statistically significant difference.
Supplementary Figure 1 from Effect of Montanide and Poly-ICLC Adjuvant on Human Self/Tumor Antigen-Specific CD4+ T Cells in Phase I Overlapping Long Peptide Vaccine Trial
Authors: Tsuji Takemasa , Sabbatini Paul , Jungbluth Achim A. , Ritter Erika , Pan Linda , Ritter Gerd , Ferran Luis , Spriggs David , Salazar Andres M. , Gnjatic Sacha
Published: April 2023

PDF file - 13027K, Comparison of apparent avidities of NY-ESO-1-specific CD4+ T cells before and after vaccination. Apparent avidity (EC50) for recognition of the NY-ESO-1 assay OLP was determined for NY-ESO-1-specific CD4+ T cell lines before and after the vaccination. (A) Cohort 1 (OLP alone); (B) Cohort 2 (OLP in Montanide); and (C) Cohort 3 (OLP and poly-ICLC in Montanide).
Table S6 from Mapping the MHC Class I–Spliced Immunopeptidome of Cancer Cells
Authors: Liepe Juliane , Sidney John , Lorenz Felix K.M. , Sette Alessandro , Mishto Michele
Published: April 2023

List of spliced and non-spliced peptides identified in the MHC-I immunopeptidomes of the two cancer cell lines, whose assigned antigen was not detected in the cell transcriptome
Table S5 from Mapping the MHC Class I–Spliced Immunopeptidome of Cancer Cells
Authors: Liepe Juliane , Sidney John , Lorenz Felix K.M. , Sette Alessandro , Mishto Michele
Published: April 2023

List of spliced and non-spliced peptides identified in the MHC-I immunopeptidomes of the two cancer cell lines and GR-LCL
Supplementary Figures 1 and 2 from Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus–Driven Production of a Bispecific T-cell Engager
Authors: Wing Anna , Fajardo Carlos Alberto , Posey Avery D. , Shaw Carolyn , Da Tong , Young Regina M. , Alemany Ramon , June Carl H. , Guedan Sonia
Published: April 2023

S1. Therapeutic index of EGFR-targeting CART cells and the OAd-BiTE. S2. The Combination of FR-CART cells and OAd-BiTE mediates tumor regression in mice bearing pancreatic xenograft tumors.
Supplementary Figure 2 from Polyamine-Blocking Therapy Reverses Immunosuppression in the Tumor Microenvironment
Authors: Hayes Candace S. , Shicora Allyson C. , Keough Martin P. , Snook Adam E. , Burns Mark R. , Gilmour Susan K.
Published: April 2023

PDF file - 668K, Central role of arginine metabolism in the immune system and its association with components of inflammatory response.
Supplementary Figure 2 from Combined Targeting of Costimulatory (OX40) and Coinhibitory (CTLA-4) Pathways Elicits Potent Effector T Cells Capable of Driving Robust Antitumor Immunity
Authors: Redmond William L. , Linch Stefanie N. , Kasiewicz Melissa J.
Published: April 2023

PDF file - 30K, Dual anti-OX40/anti-CTLA-4 therapy boosts Ag-specific CD8 T cell responses.
Supplemental Figure legends from TGFβ Inhibition Prior to Hypofractionated Radiation Enhances Efficacy in Preclinical Models
Authors: Young Kristina H. , Newell Pippa , Cottam Benjamin , Friedman David , Savage Talicia , Baird Jason R. , Akporiaye Emmanuel , Gough Michael J. , Crittenden Marka
Published: April 2023

Supplemental Figure legends from TGFβ Inhibition Prior to Hypofractionated Radiation Enhances Efficacy in Preclinical Models
Supplementary Figure Legend from Tumoral Immune Suppression by Macrophages Expressing Fibroblast Activation Protein-α and Heme Oxygenase-1
Authors: Arnold James N. , Magiera Lukasz , Kraman Matthew , Fearon Douglas T.
Published: April 2023

PDF file - 33K
Supplementary Figure 3 from Tumoral Immune Suppression by Macrophages Expressing Fibroblast Activation Protein-α and Heme Oxygenase-1
Authors: Arnold James N. , Magiera Lukasz , Kraman Matthew , Fearon Douglas T.
Published: April 2023

PDF file - 19K, Tumor sizes in the chimeric mice at the initiation of DTX administrations.
Supplementary Figure 2 from Tumoral Immune Suppression by Macrophages Expressing Fibroblast Activation Protein-α and Heme Oxygenase-1
Authors: Arnold James N. , Magiera Lukasz , Kraman Matthew , Fearon Douglas T.
Published: April 2023

PDF file - 18K, Assessment of peripheral blood chimerism of the bone marrow chimeric mice.
Supplementary Table 2 from Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma
Authors: Barker Christopher A. , Postow Michael A. , Khan Shaheer A. , Beal Kathryn , Parhar Preeti K. , Yamada Yoshiya , Lee Nancy Y. , Wolchok Jedd D.
Published: April 2023

PDF - 63KB, Prospective studies combining ipilimumab and radiation therapy for patients with unresectable and/or metastatic melanoma.
Supplementary Tables 1 - 2, Figures 1 - 3 and Methods from Granulin–Epithelin Precursor Renders Hepatocellular Carcinoma Cells Resistant to Natural Killer Cytotoxicity
Authors: Cheung Phyllis F.Y. , Yip Chi Wai , Wong Nicholas C.L. , Fong Daniel Y.T. , Ng Linda W.C. , Wan Angus M.Y. , Wong Chun Kwok , Cheung Tan To , Ng Irene O.L. , Poon Ronnie T.P. , Fan Sheung Tat , Cheung Siu Tim
Published: April 2023

Supplementary Table 1. Clinico-pathological features of HCC in relation to sGEP and sMICA levels. Supplementary Table 2. Cox regression analyses for recurrence-free survival on sGEP/sMICA levels and tumor stage. Supplementary Figure 1. Cytotoxicity of NK cells isolated by positive and negative selection. Supplementary Figure 2. Correlation between NKG2D expression on NK cells with (A) sGEP and (B) sMICA in sera of HCC patients. Supplementary Figure 3. Association of serum GEP or MICA levels with recurrence-free survival in HCC patients.
Supplementary Figure Legend from Influenza Virus Infection Elicits Protective Antibodies and T Cells Specific for Host Cell Antigens Also Expressed as Tumor-Associated Antigens: A New View of Cancer Immunosurveillance
Authors: Iheagwara Uzoma K. , Beatty Pamela L. , Van Phu T. , Ross Ted M. , Minden Jonathan S. , Finn Olivera J.
Published: April 2023

PDF file - 65K
Figure S3 from GITR Agonism Enhances Cellular Metabolism to Support CD8+ T-cell Proliferation and Effector Cytokine Production in a Mouse Tumor Model
Authors: Sabharwal Simran S. , Rosen David B. , Grein Jeff , Tedesco Dana , Joyce-Shaikh Barbara , Ueda Roanna , Semana Marie , Bauer Michele , Bang Kathy , Stevenson Christopher , Cua Daniel J. , Zúñiga Luis A.
Published: April 2023

PhosFlow and Ki67 data
Supplementary Figure 2 from Myeloid-Derived Suppressor Cells Attenuate TH1 Development through IL-6 Production to Promote Tumor Progression
Authors: Tsukamoto Hirotake , Nishikata Ryutaro , Senju Satoru , Nishimura Yasuharu
Published: April 2023

PDF file - 790K, IL-6 production related to MDSC, and phenotypic characterization of MDSC.
Supplementary Table 1 from Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer
Authors: Gulley James L. , Madan Ravi A. , Tsang Kwong Y. , Jochems Caroline , Marté Jennifer L. , Farsaci Benedetto , Tucker Jo A. , Hodge James W. , Liewehr David J. , Steinberg Seth M. , Heery Christopher R. , Schlom Jeffrey
Published: April 2023

PDF file - 43K, Antigen cascade.
Supplementary Figure 3 from Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer
Authors: Gulley James L. , Madan Ravi A. , Tsang Kwong Y. , Jochems Caroline , Marté Jennifer L. , Farsaci Benedetto , Tucker Jo A. , Hodge James W. , Liewehr David J. , Steinberg Seth M. , Heery Christopher R. , Schlom Jeffrey
Published: April 2023

PDF file - 264K, Tumor growth rates following vaccine.
Supplementary Table 2 from Splenectomy Promotes Indirect Elimination of Intraocular Tumors by CD8+ T Cells That Is Associated with IFNγ- and Fas/FasL-Dependent Activation of Intratumoral Macrophages
Authors: Miller Maxine R. , Mandell Jonathan B. , Beatty Kelly M. , Harvey Stephen A.K. , Rizzo Michael J. , Previte Dana M. , Thorne Stephen H. , McKenna Kyle C.
Published: April 2023

Mouse Strains from Jackson Laboratories used in experimentation.
Supplementary Figure 2 from CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains
Authors: Shiina Satoshi , Ohno Masasuke , Ohka Fumiharu , Kuramitsu Shunichiro , Yamamichi Akane , Kato Akira , Motomura Kazuya , Tanahashi Kuniaki , Yamamoto Takashi , Watanabe Reiko , Ito Ichiro , Senga Takeshi , Hamaguchi Michinari , Wakabayashi Toshihiko , Kaneko Mika K. , Kato Yukinari , Chandramohan Vidyalakshmi , Bigner Darell D. , Natsume Atsushi
Published: April 2023

(A) Non-specific killing was also excluded by the observation that EGFRvIII-targeting (3C10)-CAR PBMCs did not display significant lysis to LN319 cells. (B) The FACS-sorted CAR-T cells were subjected to RT-PCR. TNF-Î± was significantly produced in NZ-1 CAR-T cells that were stimulated by LN319 cells, but IL-2 and CD107a were expressed even in mock CAR-T cells, which suggested that the secretion of IL-2 and CD107a was not specific to PDPN antigen.
Supplementary Figure 1 from CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains
Authors: Shiina Satoshi , Ohno Masasuke , Ohka Fumiharu , Kuramitsu Shunichiro , Yamamichi Akane , Kato Akira , Motomura Kazuya , Tanahashi Kuniaki , Yamamoto Takashi , Watanabe Reiko , Ito Ichiro , Senga Takeshi , Hamaguchi Michinari , Wakabayashi Toshihiko , Kaneko Mika K. , Kato Yukinari , Chandramohan Vidyalakshmi , Bigner Darell D. , Natsume Atsushi
Published: April 2023

(A) Tissue array of six organs. PDPN is expressed in the basal layer of the esophagus, in the lymphatic ducts in the stomach, the colon, the rectum and the breast, and alveolar type I cells in the lung. (B) A Public database, BioGPS Dataset Library (http://biogps.org/dataset), show that the expression of PDPN is the highest in placenta with 4-fold value/brain. Error bars, Mean+95%CI. (C) The expression of GBM is 16-fold higher than that of the normal brain according to UCSC Cancer genome browser (https://genome-cancer.ucsc.edu/). Error bars, Mean+95%CI. Normal tissue array (Cybrdi, Inc., Frederick, MD) was deparaffinized and rehydrated. The tissues were then exposed to 3% hydrogen peroxidase for 5 min. An anti-human podoplanin mAb, LpMab-7 (1 ?g/ml) (1) was added to the sections for 1 h at room temperature, followed by EnVision kit (Dako) for 30 min at room temperature. Color was developed using 3, 3-diaminobenzidine tetrahydrochloride (Dako) for 2 min. The sections were counterstained with Mayer's hematoxylin.
Supplementary Figure S3 from A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration
Authors: Sakemura Reona , Terakura Seitaro , Watanabe Keisuke , Julamanee Jakrawadee , Takagi Erina , Miyao Kotaro , Koyama Daisuke , Goto Tatsunori , Hanajiri Ryo , Nishida Tetsuya , Murata Makoto , Kiyoi Hitoshi
Published: April 2023

Safety profile of Tet-CD19CAR T cells against autologous B cells.
Supplementary Figure S2 from A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration
Authors: Sakemura Reona , Terakura Seitaro , Watanabe Keisuke , Julamanee Jakrawadee , Takagi Erina , Miyao Kotaro , Koyama Daisuke , Goto Tatsunori , Hanajiri Ryo , Nishida Tetsuya , Murata Makoto , Kiyoi Hitoshi
Published: April 2023

CAR expression and the subsequent function of Tet-CD19CAR T cells can be precisely regulated in a dose-dependent manner.
Supplementary Tables 1-3 from IL10R2 Overexpression Promotes IL22/STAT3 Signaling in Colorectal Carcinogenesis
Authors: Khare Vineeta , Paul Gregor , Movadat Oliver , Frick Adrian , Jambrich Manuela , Krnjic Anita , Marian Brigitte , Wrba Friedrich , Gasche Christoph
Published: April 2023

Supplementary Table 1. Primers used for qRT-PCR. Supplementary Table 2. MSI markers. Supplementary Table 3. Primers used for copy number varation (CNV) analysis.
Supplementary Figures 1-4 from IL10R2 Overexpression Promotes IL22/STAT3 Signaling in Colorectal Carcinogenesis
Authors: Khare Vineeta , Paul Gregor , Movadat Oliver , Frick Adrian , Jambrich Manuela , Krnjic Anita , Marian Brigitte , Wrba Friedrich , Gasche Christoph
Published: April 2023

Supplementary Figure 1. IL-10 signaling genes in CRC cell lines. Supplementary Figure 2. Association of IL-10R2 expression with MSS phenotype. Supplementary Figure 3. Overexpression of IL-10R2. Supplementary Figure 4. (A) Immunoreactivity scores (IRS) of IL-22 and its receptors. (B) Interaction of IL-10R2 and IL-22R1in CRC cells.
Supplementary Methods from Long-term Complete Remission Following Radiosurgery and Immunotherapy in a Melanoma Patient with Brain Metastasis: Immunologic Correlates
Authors: Karbach Julia , Gnjatic Sacha , Biskamp Melina , Atmaca Akin , Weidmann Eckhart , Brandt Kathrin , Wahle Claudia , Bernhard Helga , Knuth Alexander , Jäger Elke
Published: April 2023

PDF file - 78K
Supplementary Figure S7 from IFNγ Induces DNA Methylation–Silenced GPR109A Expression via pSTAT1/p300 and H3K18 Acetylation in Colon Cancer
Authors: Bardhan Kankana , Paschall Amy V. , Yang Dafeng , Chen May R. , Simon Priscilla S. , Bhutia Yangzom D. , Martin Pamela M. , Thangaraju Muthusamy , Browning Darren D. , Ganapathy Vadivel , Heaton Christopher M. , Gu Keni , Lee Jeffrey R. , Liu Kebin
Published: April 2023

Figure S7. Model of transcriptional activation of GPR109A by IFN-gamma from its methylated promoter.
Supplementary Table 2 from Effector Regulatory T Cells Reflect the Equilibrium between Antitumor Immunity and Autoimmunity in Adult T-cell Leukemia
Authors: Ureshino Hiroshi , Shindo Takero , Nishikawa Hiroyoshi , Watanabe Nobukazu , Watanabe Eri , Satoh Natsuko , Kitaura Kazutaka , Kitamura Hiroaki , Doi Kazuko , Nagase Kotaro , Kimura Hiromi , Samukawa Makoto , Kusunoki Susumu , Miyahara Masaharu , Shin-I Tadasu , Suzuki Ryuji , Sakaguchi Shimon , Kimura Shinya
Published: April 2023

The numbers of sequence reads
Supplementary Figure S6 from IFNγ Induces DNA Methylation–Silenced GPR109A Expression via pSTAT1/p300 and H3K18 Acetylation in Colon Cancer
Authors: Bardhan Kankana , Paschall Amy V. , Yang Dafeng , Chen May R. , Simon Priscilla S. , Bhutia Yangzom D. , Martin Pamela M. , Thangaraju Muthusamy , Browning Darren D. , Ganapathy Vadivel , Heaton Christopher M. , Gu Keni , Lee Jeffrey R. , Liu Kebin
Published: April 2023

Figure S6. IFN-gamma induces chromatin remodeling in the GPR109A promoter regions.
Supplementary Figure S4 from IFNγ Induces DNA Methylation–Silenced GPR109A Expression via pSTAT1/p300 and H3K18 Acetylation in Colon Cancer
Authors: Bardhan Kankana , Paschall Amy V. , Yang Dafeng , Chen May R. , Simon Priscilla S. , Bhutia Yangzom D. , Martin Pamela M. , Thangaraju Muthusamy , Browning Darren D. , Ganapathy Vadivel , Heaton Christopher M. , Gu Keni , Lee Jeffrey R. , Liu Kebin
Published: April 2023

Figure S4: Immunohistochemical staining of CD4+ T cell infiltration level in colon carcinoma tissues from 10 patients. The brown color indicates specific CD4+ T cells.
Supplementary Figure S2 from IFNγ Induces DNA Methylation–Silenced GPR109A Expression via pSTAT1/p300 and H3K18 Acetylation in Colon Cancer
Authors: Bardhan Kankana , Paschall Amy V. , Yang Dafeng , Chen May R. , Simon Priscilla S. , Bhutia Yangzom D. , Martin Pamela M. , Thangaraju Muthusamy , Browning Darren D. , Ganapathy Vadivel , Heaton Christopher M. , Gu Keni , Lee Jeffrey R. , Liu Kebin
Published: April 2023

Figure S2. Effects of cytokines on GPR109A expression in human colon carcinoma cells.
Supplementary Figures 1 through 5 and supplementary Tables 1 through 3 from Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature
Authors: Melief Sara M. , Visconti Valeria V. , Visser Marten , van Diepen Merel , Kapiteijn Ellen H.W. , van den Berg Joost H. , Haanen John B.A.G. , Smit Vincent T.H.B.M. , Oosting Jan , van der Burg Sjoerd H. , Verdegaal Els M.E.
Published: April 2023

Figure S1. Kaplan-meier curves of the ACT-treated patients. Figure S2. Immunofluorescent staining of metastatic melanoma tissue with antibodies against CD3, CD8, FoxP3, CD14, CD163, galectin-1, galectin-3 and galectin-9. Figure S3. Macrophage and Tbet staining Figure S4. Interaction analyses of immune markers that are prognostic for survival Figure S5. Interaction analysis and immune signature of survival cohorts Table S1A. Immunoreactive score (IRS): scoring of staining intensity of markers expressed by tumor cells. S1B. Patient characteristics Table S2A. Number of infiltrating immune cells and expression of galectin-1 and galectin-3. Table S2B. Correlation between all analyzed immune markers Table S3. Immune signatures of the patients showing clinical benefit after ACT.
Supplementary Figure 8 from Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses
Authors: Beavis Paul A. , Milenkovski Nicole , Henderson Melissa A. , John Liza B. , Allard Bertrand , Loi Sherene , Kershaw Michael H. , Stagg John , Darcy Phillip K.
Published: April 2023

This supplementary figure shows the phenotype of tumor-infiltrating lymphocytes following PD-1 or PD-1/A2A blockade.
Supplementary Figure 3 from PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer
Authors: Severson Jill J. , Serracino Hilary S. , Mateescu Valerica , Raeburn Christopher D. , McIntyre Robert C. , Sams Sharon B. , Haugen Bryan R. , French Jena D.
Published: April 2023

Supplementary Figure 3. Stimulated Cytokine Production in Peripheral Blood T Cells. Lymphocytes from peripheral blood (A) or normal LN (B) were stimulated with PMA/ionomycin and analyzed by flow cytometry for cytokine expression. CD8+ or CD4+ T cells from PD-1loTim-3- (filled shapes) and PD-1+Tim-3+ (open shapes) TILN were compared for frequencies of IL-2+, TNFα+, and IFNγ+ cells. Mean and SEM are shown. No statistically significant differences were observed.
Supplementary Figure 6 from Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses
Authors: Beavis Paul A. , Milenkovski Nicole , Henderson Melissa A. , John Liza B. , Allard Bertrand , Loi Sherene , Kershaw Michael H. , Stagg John , Darcy Phillip K.
Published: April 2023

This supplementary Figure shows the proportion and PD-1 expression on tumor-infiltrating lymphocytes following PD-1 or PD-1/A2A blockade.
Supplementary Figure 1 from PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer
Authors: Severson Jill J. , Serracino Hilary S. , Mateescu Valerica , Raeburn Christopher D. , McIntyre Robert C. , Sams Sharon B. , Haugen Bryan R. , French Jena D.
Published: April 2023

Supplementary Figure 1. PD-1+ T cells in TILN are largely CD45RO+RA-CCR7- effector memory cells (TEM). T cells from PB, normal lymph node, and TILN sections from patients 11 and 12 were analyzed by flow cytometry. CD8+ and CD4+ CD3+ T cells were gated assessed for expression of CD45RA, CD45RO, CCR7 and CD62L. PD-1+ populations were analyzed for memory marker phenotype in patients 11 and 12.
Supplementary Figure 1 from Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses
Authors: Beavis Paul A. , Milenkovski Nicole , Henderson Melissa A. , John Liza B. , Allard Bertrand , Loi Sherene , Kershaw Michael H. , Stagg John , Darcy Phillip K.
Published: April 2023

This Supplememntary Figure shows the effect of combined PD-1 and A2A blockade on in vitro effector functions of OT-I cells.
supplemental S-1 from The Inhibitory Signaling Receptor Protocadherin-18 Regulates Tumor-Infiltrating CD8+ T-cell Function
Authors: Frey Alan B.
Published: April 2023

pcdh 18 is expressed in anti-L. monocytogenes (SIINFEKL-specific) CD8+ T cells.
Supplementary Figure 4 from Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor
Authors: Tähtinen Siri , Grönberg-Vähä-Koskela Susanna , Lumen Dave , Merisalo-Soikkeli Maiju , Siurala Mikko , Airaksinen Anu J. , Vähä-Koskela Markus , Hemminki Akseli
Published: April 2023

Supplementary Figure S4: Immune cell subsets in the tumors following combination treatment.
Supplemental S-3 from The Inhibitory Signaling Receptor Protocadherin-18 Regulates Tumor-Infiltrating CD8+ T-cell Function
Authors: Frey Alan B.
Published: April 2023

Expression of immune cell molecules in wild type and pcdh 18 -/- CD8+ T spleen cells.
Supplemental Figures and Legends from The Inhibitory Signaling Receptor Protocadherin-18 Regulates Tumor-Infiltrating CD8+ T-cell Function
Authors: Frey Alan B.
Published: April 2023

Supplemental Figures 1-6
Supplementary Figure 3 from Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen
Authors: Sharabi Andrew B. , Nirschl Christopher J. , Kochel Christina M. , Nirschl Thomas R. , Francica Brian J. , Velarde Esteban , Deweese Theodore L. , Drake Charles G.
Published: April 2023

Supp Figure 3. Example of multiparameter flow cytometry gating scheme.
Supplementary Figure 2 from Gene-Modified Human α/β-T Cells Expressing a Chimeric CD16-CD3ζ Receptor as Adoptively Transferable Effector Cells for Anticancer Monoclonal Antibody Therapy
Authors: Ochi Fumihiro , Fujiwara Hiroshi , Tanimoto Kazushi , Asai Hiroaki , Miyazaki Yukihiro , Okamoto Sachiko , Mineno Junichi , Kuzushima Kiyotaka , Shiku Hiroshi , Barrett John , Ishii Eiichi , Yasukawa Masaki
Published: April 2023

PDF file - 4938K, A. Representative patterns of tumor growth displayed in mice treated with cCD16ζ-T cells in combination with rituximab in the late phase determined using in vivo bioluminescence assay. In mice treated with cCD16ζ-T cells combined with rituximab, tumor growth at truncal sites appeared to be durably localized and suppressed. However, the brain lesion showed obvious progression, even after the second therapeutic infusion on day 24. On day 32, the cCD16ζ-T-No.8 mouse was euthanatized to examine the persistence of therapeutically infused effector cells in the spleen and BM. B. In cCD16ζ-T-No.8 mouse, all detected human cells in both the spleen and BM were CD3+ T cells, and not CD20+ Raji cells. About 20% of these residual T cells displayed cell-surface CD16, i.e., cCD16ζ-T cells defined as hCD45+CD3+CD16+. C. cCD16ζ-T cells in both the spleen (upper) and BM (lower) retained their responsiveness exclusively against rituximab-opsonized Raji cells, reflected as increased expression of CD107a.
Supplementary Figure 3 from Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer
Authors: Cullis Jane , Siolas Despina , Avanzi Antonina , Barui Sugata , Maitra Anirban , Bar-Sagi Dafna
Published: April 2023

Nab-paclitaxel induces M1 activation in pancreatic tumor-associated macrophages in vivo
Supplementary Figure S5 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Authors: Winograd Rafael , Byrne Katelyn T. , Evans Rebecca A. , Odorizzi Pamela M. , Meyer Anders R.L. , Bajor David L. , Clendenin Cynthia , Stanger Ben Z. , Furth Emma E. , Wherry E. John , Vonderheide Robert H.
Published: April 2023

Supplementary Figure S5. T cell changes following αCD40/chemotherapy treatment.
Supplementary Figure S2 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Authors: Winograd Rafael , Byrne Katelyn T. , Evans Rebecca A. , Odorizzi Pamela M. , Meyer Anders R.L. , Bajor David L. , Clendenin Cynthia , Stanger Ben Z. , Furth Emma E. , Wherry E. John , Vonderheide Robert H.
Published: April 2023

Supplementary Figure S2. PD-L1 expression on lineage labeled PDA cells in vivo.
Supplemenatry Figure Legends from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Authors: Winograd Rafael , Byrne Katelyn T. , Evans Rebecca A. , Odorizzi Pamela M. , Meyer Anders R.L. , Bajor David L. , Clendenin Cynthia , Stanger Ben Z. , Furth Emma E. , Wherry E. John , Vonderheide Robert H.
Published: April 2023

Supplementary Figure Legends
Supplemental Figure 2 from Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma
Authors: Tran Linda , Allen Clint T. , Xiao Roy , Moore Ellen , Davis Ruth , Park So-Jin , Spielbauer Katie , Van Waes Carter , Schmitt Nicole C.
Published: April 2023

S2. Low-dose cisplatin and anti-PD-L1 blockade in combination modestly delayed tumor growth but did not prolonged survival in MOC1 tumor-bearing mice. Mice were injected with 5 x 106 MOC1 tumor cells in the right flank. After 11 days, mice with palpable tumors were randomized and treated concurrently with cisplatin (3 mg/kg/week x 4 weeks) and/or anti-PD-L1 antibody (200 mcg twice/week x 3 doses). Black line: control; Blue line: CDDP only; Gray line: anti-PD-L1; Green line: combination. Data are from the same experiment shown in Fig. 3. A, Tumor volume over time. Data are mean {plus minus} SEM, n = 7-8 mice per group. **p<0.01 vs. control by linear regression curve comparison. B, Kaplan-Meier survival plot.
Supplementary Figure 6 from Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma
Authors: Griesinger Andrea M. , Josephson Rebecca J. , Donson Andrew M. , Mulcahy Levy Jean M. , Amani Vladimir , Birks Diane K. , Hoffman Lindsey M. , Furtek Steffanie L. , Reigan Phillip , Handler Michael H. , Vibhakar Rajeev , Foreman Nicholas K.
Published: April 2023

IL-6 is the driving cytokine for immune suppressive phenotype observed in 811 CM monocytes.
Supplementary Figure 4 from Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma
Authors: Griesinger Andrea M. , Josephson Rebecca J. , Donson Andrew M. , Mulcahy Levy Jean M. , Amani Vladimir , Birks Diane K. , Hoffman Lindsey M. , Furtek Steffanie L. , Reigan Phillip , Handler Michael H. , Vibhakar Rajeev , Foreman Nicholas K.
Published: April 2023

Concentration of cytokine secretion from flow sorted disaggregated tumor samples.
Supplementary Methods and Figure Legends from Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies
Authors: Evans Elizabeth E. , Jonason Alan S. , Bussler Holm , Torno Sebold , Veeraraghavan Janaki , Reilly Christine , Doherty Michael A. , Seils Jennifer , Winter Laurie A. , Mallow Crystal , Kirk Renee , Howell Alan , Giralico Susan , Scrivens Maria , Klimatcheva Katya , Fisher Terrence L. , Bowers William J. , Paris Mark , Smith Ernest S. , Zauderer Maurice
Published: April 2023

Analysis and statistics for tumor growth, survival and CR: Immunohistochemistry methods.
Supplementary Figure 3 from Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma
Authors: Griesinger Andrea M. , Josephson Rebecca J. , Donson Andrew M. , Mulcahy Levy Jean M. , Amani Vladimir , Birks Diane K. , Hoffman Lindsey M. , Furtek Steffanie L. , Reigan Phillip , Handler Michael H. , Vibhakar Rajeev , Foreman Nicholas K.
Published: April 2023

Ratio of Group A EPN IL6/STAT3 pathway genes in tumor versus the myeloid compartments.